



PRESS RELEASE

## ***Publication of the Interim Financial Report at June 30<sup>th</sup> 2018***

Milan (Italy), August 1<sup>st</sup>, 2018 – The Interim Financial Report at June 30<sup>th</sup> 2018 of MolMed S.p.A. (MLMD.MI), including the External Auditor' Review report on condensed financial statement, is available to the public on the authorised storage device 1Info-Storage ([www.1info.it](http://www.1info.it)) and on the Company website [www.molmed.com](http://www.molmed.com).

### ***About MolMed***

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

### ***For further information:***

#### ***Ilaria Candotti***

#### ***Investor Relations & Communication Manager***

MolMed S.p.A.

phone: +39 02 21277.205

fax: +39 02 21277.325

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

#### ***Marcella Ruggiero***

#### ***Press agent***

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991

mobile +39 335 214241

e-mail: [ruggiero@segrp.com](mailto:ruggiero@segrp.com)